Founder of Dovetail Technologies, LifeTime Pharmaceuticals and FindCure.Org, the organizations that coordinated to take the first drug that modulates immune checkpoint molecules into clinical trials.
Head biomedical scientist/pathologist at OTraces, Veramarx, ClearCreek Partners, AccuBiome and AxImmune.
CEO of CytoCore, CYOE
Founder of Digene, the company that changed the screening for cervical cancer. Digene developed the first clinical nucleic acid test for cancer or precancer.
National Institutes of Health (NIH) including heading a pathology unit.
George Washington University
University of Colorado Medical Center
Northwestern University. M.D.
Over 50 publications, presentations and patent applications
Executive-in-Residence at CU Innovations
Founder, CEO and board member of medical diagnostics and device companies for over 30 years.
Founder of Cytyc Corp (NASDA :CYTC) He is the principal inventor of gyty,cATJi,rDrep,Pap test which revolutionized screening for cervical cancer accounting for —70% of the world market for cervical cancer screening. Cytyc was acquired by Hologic for $6.2 billion in 2007.
Founder of EXACT Sciences Corp. (NASDAQ:EXAS) and served as CEO and Chairman. EXACT pioneered high-accuracy non-invasive testing for early detection of colorectal cancer. Since the commercial introduction of the company's Cologuard test, EXACT has been the most rapidly growing company in the history of the diagnostics industry.
Stan holds 37 US patents.
Fellow of the American Institute of Medical and Biological Engineering in 2013 for his work on the early detection of cancer.
He currently serves as a director of a number of public and private medical device and diagnostics companies.
Roche Diabetes Care –
Inventor on Roche Electrochemistry patents
Director of the Center for Entrepreneurship, Colorado School of Mines
Technology Commercialization Director and the founding Director of the Stevens Venture Center
Professor Adjoint of Chemistry University of Colorado where he developed electrochemical methods and microfluidic devices
Vice President of Research at ZettaCore, Inc., a company he founded and sold into the semiconductor and printed circuit board industry.
At UC Riverside, he ran a research program that graduated 25 Ph.D. and MS students in fifteen years, published roughly 100 papers (H-index = 60)
He has participated in the formation of five start-up technology companies, several of which were based on translation research in protein diagnostics and genomics
Professor of Chemistry and Chemical & Biological Engineering 18 years
Chair of the Department of Chemistry (since 2014).
Dr. Henry’s research interests lie broadly in the development of lab-on-a-chip technologies
Major techniques used include microfabrication, chromatography, electrochemistry, electrophoresis, microfluidics, microscopy, and 3D printing, paper based diagnostic devices
Over 120 peer-reviewed publications, 8 patents
Editorial board for Analytica Chimica Acta.
Five spin-out companies from Colorado State University